Default company panoramic image

Crescent Diagnostics

Crescent Diagnostics is a clinical diagnostics firm developing a proprietary predictive test for osteoporosis - BQT®.

  • Stage Concept Only
  • Industry Medical Devices and Equipment
  • Location Dublin, Ierland
  • Currency EUR
  • Website

Company Summary

Osteoporosis-related fractures impose costs of €26bn in the EU and $19 bn in the US each year. Crescent is developing BQT, a 5-minute non-invasive predictive test for bone quality and hip fracture risk. This will enable clinicians to identify those who are at high risk of suffering a hip fracture – the most devastating consequence of osteoporosis. Appropriate interventions can then be made to help patients avoid this preventable disease.


  • Default avatar
    Brendan K Farrell MSc
    Chief Executive Officer

    Brendan has over 30 years international experience in the diagnostics industry. He was formerly President/CEO of Trinity Biotech Plc, a NASDAQ-listed diagnostics company, which he grew from revenues of $3m to $140m. He was also CEO of VC funded startup Noctech Ltd, which he sold for a 6x revenue multiples. Brendan is currently Executive Chairman of Hibergene Diagnostics Ltd.

  • Default avatar
    Dave McGeady MSc MBA
    Business Development Director

    Dave completed an MSc. in Industrial Engineering & Management from Helsinki University of Technology and graduated with a first from Trinity College Dublin. Dave graduated magna cum laude from the MBA program at Tel Aviv University while also making the Dean's list on exchange at Kellogg School of Management. Dave is a member of Beta Gamma Sigma and previously worked in investment banking with Bank of America’s healthcare team.

  • Default avatar
    Gill Morgan PhD
    Chief Operating Officer

    Gill has worked since 1989 in the diagnostics industry, with 10 years based in North America. Gill’s expertise is in clinical trials, product registration and quality systems. She headed the global regulatory and clinical groups at Bayer Diagnostics for 5 years, and has held senior functional and executive management roles in SMEs, most recently as Chief Development Officer at Myconostica, a molecular diagnostics company.

  • Default avatar
    Orlaith Brennan PhD
    Clinical Project Manager

    Orlaith has extensive expertise in bone quality assessment, mechanical characterisation of biological tissues and bone cell biology, having carried out a PhD on "Bone Quality and its Relationship with Bone Fragility and Osteoporosis" at Royal College of Surgeons in Ireland and worked at research laboratories in Australia, the UK and Ireland. Orlaith is a graduate in Experimental Physics from Trinity College Dublin, from where she also holds an MS

  • Default avatar
    Renwick Beattie PhD
    Senior Scientific Officer

    Renwick has over a decade of experience working at the interface of spectroscopy and biomedicine. His work at Queen’s University of Belfast focused on the development and application of Raman spectroscopic methods in the analysis of biomedical issues. He has published the results of his extensive research in 24 peer reviewed internationally recognised scientific journals and at numerous international conferences.

  • Default avatar
    Marie Rooney MSc
    Project Director

    Marie has 20 years’ general management experience in the healthcare industry with particular experience in. Ms. Rooney was Operations Manager with Trinity Biotech Plc. Previously, Marie was an R&D scientist with Cambridge Diagnostics Ltd., a wholly owned subsidiary of Inverness Medical Innovations inc. Marie is a graduate of the University of Limerick and holds a Masters degree in Project Management.